The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.
No takes yet. Share an insight, caveat, or question.
Jensen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: